Form Approved OMB Control No.: 0920-1310

Expiration date: XX/XX/XXXX

Annual Evaluation and Performance Measurement Report (I.13- ANTIMICROBIAL SUSCEPTIBILITY TESTING (AST) OF INVASIVE HAEMOPHILUS INFLUENZAE (H. INFLUENZAE) IN JURISDICTION)

Annually, each funded laboratory is required to report to CDC evaluation and performance measures. Data are used to indicate progress made toward program outcomes. These summary reports have to be uploaded to the ELC CAMP at the end of each funding year. Required performance measures are listed below.

	Antibiotic:	Total Number (N) of H. influenzae Isolates with QC-passed br microdilution
1.	Rifampin	
2.	Ampicillin	
3.	Amoxicillin-clavulanate	
4.	Chloramphenicol	
5.	Cefotaxime	
6.	Ceftriaxone	
7.	Cefuroxime	
8.	Clarithromycin	
9.	Levofloxacin	
10	. Meropenem	
11	. Tetracycline	
12	. Trimethoprim-sulfamethoxazole	
Prop	ortion of isolates with AST results reported to submitting sites w	vithin 3 weeks of submission:
a.	Numerator: Number of isolates with AST results reported to sub-	· ·
b.	Denominator: Number of HI isolates received at AR Lab Network	
C.	Calculated: Percentage of isolates with AST results reported to se	entinel sites within 3 weeks of submission
	ortion of isolates with AST results reported to CDC-Bacterial Me	• , , , ,
	Numerator: Number of isolates with AST results reported to CDC quarterly.	
	Denominator: Number of HI isolates received at AR Lab Network.	
c. Ca	lculated: Percentage of isolates with AST results reported to CDC of	quarteriy.
Prop	portion of isolates transported to CDC-BML within 6 months:	
a.	Numerator: Number of isolates transported to CDC	
b.	Denominator: Total number of HI isolates received at AR Lab Net	
C.	Calculated: Percent of isolates transported to CDC within 6 mont	hs

Public reporting burden of this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB Control Number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer, 1600 Clifton Road NE, MS H21-8, Atlanta, Georgia 30333; ATTN: PRA 0920-1310